Delgado-Escueta, A.V. ; Ganesh, Subramaniam ; Yamakawa, Kazuhiro (2001) Advances in the genetics of progressive myoclonus epilepsy American Journal of Medical Genetics, 106 (2). pp. 129-138. ISSN 0148-7299
Full text not available from this repository.
Official URL: http://onlinelibrary.wiley.com/doi/10.1002/ajmg.15...
Related URL: http://dx.doi.org/10.1002/ajmg.1575
Abstract
The genetic progressive myoclonus epilepsies (PMEs) are clinically characterized by the triad of stimulus sensitive myoclonus (segmental lightning like muscular jerks), epilepsy (grand mal and absences) and progressive neurologic deterioration (dementia, ataxia, and various neurologic signs depending on the cause). Etiologically heterogenous, PMEs are rare and mostly autosomal recessive disorders, with the exception of autosomal dominant dentatorubral-pallidoluysian atrophy and mitochondrial encephalomyopathy with ragged red fibers (MERRF). In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Wiley. |
ID Code: | 102826 |
Deposited On: | 01 Feb 2017 17:03 |
Last Modified: | 01 Feb 2017 17:03 |
Repository Staff Only: item control page